ClinicalTrials.gg
CompletedNCT02432937Updated Nov 4, 2016

Corever in the Treatment of Hypertension

A Phase 3 interventional study of Corever in Hypertension, sponsored by TSH Biopharm Corporation Limited. Completed at 8 sites in Taiwan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-11-04.

Sponsored by TSH Biopharm Corporation Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
20 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 116 studies in Hypertension with a site in Taiwan — 17 open to participants now, 20 under way, 5 of them phase 3. Hypertension · Taiwan.

Enrollment
55th of 90
134 · median 233
Started
2015
with 1 other
Phase 3
26 of 116
4 open now
Registered
59th of 116
by date

Among the 116 studies in Hypertension with a site in Taiwan, this one is the 55th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2015, is one of 26 in phase 3, and was the 59th registered.

Hypertension

6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

17 of the 116 studies in Hypertension with a site in Taiwan are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Hypertension with a site in Taiwan, or all of them as a file.
02

Study summary

The study primarily aims to compare the effects of two doses of Corever with placebo in patients with hypertension.

Read the detailed description

The study aims to compare the effects of two doses of Corever with placebo in patients with essential hypertension. Eligible subjects who belong to one of the following subtypes are planned to be enrolled: (1) patients with essential hypertension without drug control, or (2) uncontrolled hypertension despite treatment with up to 2 antihypertensive agents. Of note, the second category will receive randomized study treatments in addition to continuing their previous medication throughout the trial. The study also wants to investigate the safety profile of Corever during treatment period.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Corever
  • hypertension
04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are 20-90 years of age
  2. Patients who belong to either one of the following categories:

    With essential hypertension, as measured by office BP and are not on antihypertensive treatment at screening .

    With uncontrolled hypertension despite treatment with up to 2 antihypertensive agents, and the type and dose of the agents shall be maintained for at least 28 days prior to entering this trial.

  3. Agree to and are able to follow the study procedures.
  4. Understand the nature of the study, and have signed forms.

Exclusion criteria

Exclusion Criteria:

  1. Patients with any of the following conditions:

    • Malignant hypertension
    • Secondary hypertension
    • Average sitting SBP ≥ 180 mmHg
    • Advanced hypertensive retinopathy
    • Type 1 diabetes
    • Acute coronary syndrome
    • Clinical significant valvular disease
    • Hypertrophic cardiomyopathies
    • class III -IV congestive HF
    • Second or third degree atrioventricular block or history of sick sinus syndrome unless a pacemaker is in place
    • Atrial fibrillation
    • Sinus bradycardia (\<60 bpm)
    • Asthma
    • Stroke within 3 months
    • Cancer with expected survival less than 3 years
    • A difference of > 20 mmHg for SBP or > 10 mmHg for DBP between arms at screening
    • Severe hepatic impairment
    • A history of a serious reaction.
  2. Patients with abnormalities.
  3. Patients with known to Corever.
  4. Female patients who are pregnant or lactating.
    1. Male or female patients of who do not agree to use an effective method of during the study.
  5. Patients is currently participating in any other clinical trial within 30 days
  6. Patients need to be treated with the permitted medication.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
134 participants (actual)

Study arms

  • Placebo comparator
    Corever middle dose

    Drug: Corever

  • Placebo comparator
    Corever high dose

    Drug: Corever

  • Placebo comparator
    Placebo

    Drug: Corever

Interventions

  • DrugCorever

    Corever

    Also known as: CRTA04

06

What researchers measure

Primary outcomes

  1. Seated Office SBP reduction (SBP each visit-SBP visit 2)

    To compare the change in office SBP measurements by cuff assessments after 8 weeks of treatment

    Time frame: 8 weeks

Secondary outcomes

  1. Seated Office DBP reduction (DBP each visit-DBP visit 2)

    1. To compare the change in office DBP measurements by cuff assessments after 8 weeks of treatment 2. To compare the percentage of subjects who achieve BP goal as measured by cuff assessments (140/90 mmHg) after 8 weeks of treatment

    Time frame: 8 weeks

Other outcomes

  1. Safety-Adverse events

    Time frame: 8 weeks

  2. Safety-Changes in vital signs

    Time frame: 8 weeks

  3. Safety-Changes in laboratory examinations

    Time frame: 8 weeks

  4. Safety-Changes in electrocardiograms

    Time frame: 8 weeks

07

Study locations

8 sites
  • Hualien Tzu Chi Hospital
    Hualien, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Shin Kong Wu Ho-Su Memorial Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jun 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2015
First posted
May 4, 2015
Start
Jan 2015
Primary completionActual
Jun 2016
CompletionActual
Aug 2016
Last update
Nov 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02432937
Lead sponsor
TSH Biopharm Corporation Limited
Responsible party
Sponsor
First posted
May 4, 2015
Start date
Jan 2015
Primary completion
Jun 2016
Completion
Aug 2016
Last update
Nov 4, 2016

Study contacts

Chern-En Chiang, M.D., Ph.D.,
principal investigator · Taipei Veterans General Hospital, Taiwan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion